美股異動 | 諾瓦瓦克斯醫藥市前大升30%,候選疫苗進行一期臨床試驗
uSMART友信智投5月26日消息,週二美股市前,諾瓦瓦克斯醫藥(NVAX.US)市前飆升30%,截至北京時間16時03分,諾瓦瓦克斯醫藥升32.29%,報61美元。

根據消息,諾瓦瓦克斯醫藥近日表示,已開始對代號為NVX-CoV2373的候選疫苗進行一期臨床試驗,預計將於7月發佈初步的免疫原性和安全性結果。
該公司表示,計劃在澳大利亞的兩個地點招募約130名年齡在18至59歲的健康人士參與第一階段的研究。
如果成功,諾瓦瓦克斯醫藥將在包括美國在內的多個國家開展第二階段研究,並將在更大的年齡範圍內測試疫苗是否能降低患病風險。
公司首席執行官斯坦利•埃爾克表示,已經開始擴大生產規模,但還不知道疫苗是否能在研究中證明安全有效。
免責聲明:本文所載的所有資料、資料等(「資料」)只供參考之用,不構銷售或建議任何投資、交易策略或金融產品的要約或招攬。本公司會盡力確保資料的準確性及可靠性, 但不保證該資料為準確無誤, 亦不承擔因任何不準確或遺漏而引起的損失或損害。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of this article is for reference only. It does not constitute an offer, solicitation, recommendation, opinion or guarantee of any securities, financial products or instruments.The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance.